Roche Holding AG (RHHBF)
| Market Cap | 264.31B |
| Revenue (ttm) | 68.85B |
| Net Income (ttm) | 9.13B |
| Shares Out | n/a |
| EPS (ttm) | 11.38 |
| PE Ratio | 28.94 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3 |
| Average Volume | 94 |
| Open | 345.40 |
| Previous Close | 360.00 |
| Day's Range | 345.40 - 345.40 |
| 52-Week Range | 254.81 - 380.00 |
| Beta | 0.22 |
| RSI | 50.39 |
| Earnings Date | Apr 25, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
Sarepta Therapeutics Inc . (NASDAQ: SRPT) reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents . Quarterly revenue ...
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
Net product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year ELEVIDYS net product revenue for the first quarter totaled $375.0 million...
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
– Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025 , NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephien...
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million ; Adjusted EBIT...
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity
Basel, 06 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its Elecsys® PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients ...
Hanover Insurance CEO on tariffs: Situation is manageable due to cost visibility
Jack Roche, The Hanover Group CEO, joins 'The Exchange' to discuss the company's quarterly earnings results, how tariffs are impacting Roche's business, what's next for insurance premiums, and much mo...
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion dealto develop Danish biotechZealand Pharma's "next generation" weight loss drug.
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeuti...
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Blood-Based Biomarkers (BBB) Market Review 2023-2024 and Growth Opportunities 2025-2035 Featuring Profiles of Key Players - Roche, Sysmex Corporation, MiRXES, Minomic, Creative Diagnostics and More
Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Blood-Based Biomarker Market - A Global and Regional Analysis: Focus on Disease, Application, and Country-Level Analysis, 2025-2035" report has been add...
CHMP recommends EU label update for Roche's Phesgo to allow administration outside of clinical settings
Basel, 30 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recom...
David Roche: U.S. dollar is likely to drop another 15-20%, causing a sell-off of treasuries
David Roche of Quantum Strategy says a weaker dollar will drive 10-year yields to 5.5%, which will threaten the dollar's dominance. He says the Fed can do little to prevent this selling of treasuries.
'Roche could've earned over 100 times what it cost for rare disease drug'
Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its development costs. Roche disputes this, citing expenses from unsuccessful proj...
Notable healthcare headlines for the week: Merck, Roche and Bausch Health in focus
Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4
Zealand Pharma says obesity drug deal with Roche will help it stay independent
Danish biotech is developing petrelintide in partnership with the Swiss pharma group
Roche: Key Products Stall, Obesity Pipeline Takes Shape
Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging. See why RHHBY stock is a buy.
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
Basel, 25 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluz...
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detail...
Roche Holding AG (RHHBY) Q1 2025 Sales/ Trading Statement Call Transcript
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in premarket trades.
EU pharma majors Sanofi, Roche trade flat after reiterated guidance
Roche seeks US tariff relief in direct talks with Trump administration
Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products it ships into the United States are offset by its exports of U.S.-made drugs...
Roche Sales Rise, Boosted By Key Drugs
Roche posted higher sales that beat analysts' expectations on higher demand for its key drugs.
Roche says Q1 sales up 7%, confirms guidance
Swiss drugmaker Roche said on Thursday its first-quarter sales rose 7% to 15.44 billion Swiss francs ($18.64 billion) and it confirmed its full-year guidance.
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
Basel, 23 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navifyⓇ Algorithm Suite. This groundbreaking alg...